Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Genetron Holdings Limited is a diagnostics & research business based in the US. Genetron shares (GTH) are listed on the NASDAQ and all prices are listed in US Dollars. Genetron employs 799 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $4.69 |
|---|---|
| 52-week range | $4.91 - $31.54 |
| 50-day moving average | $9.31 |
| 200-day moving average | $15.39 |
| Wall St. target price | $14.45 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.69 from 2022-01-14
| 1 week (2022-01-10) | -6.20% |
|---|---|
| 1 month (2021-12-17) | -34.13% |
| 3 months (2021-10-15) | -65.57% |
| 6 months (2021-07-16) | -75.47% |
| 1 year (2021-01-15) | -76.66% |
|---|---|
| 2 years (2020-01-13) | N/A |
| 3 years (2019-01-13) | N/A |
| 5 years (2017-01-13) | N/A |
| Revenue TTM | $519 million |
|---|---|
| Gross profit TTM | $260.2 million |
| Return on assets TTM | -12.46% |
| Return on equity TTM | -25.45% |
| Profit margin | -78.37% |
| Book value | $15.00 |
| Market capitalisation | $444.4 million |
TTM: trailing 12 months
We're not expecting Genetron to pay a dividend over the next 12 months.
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.